Geneva, Switzerland and New York, USA, April 3, 2024 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company pioneering allosteric modulation-based drug development, ...
Ranjan K. Singh, Ahmed Soliman, Giambattista Guaitoli, Eliza Störmer, Felix von Zweydorf, Thomas Dal Maso, Asmaa Oun, Laura Van Rillaer, Sven H. Schmidt, Deep ...
At ESMO 2025, pharmaphorum had the pleasure of speaking with Michael Lahn, Chief Medical Officer at iOnctura, a clinical-stage precision oncology company combatting neglected and hard-to-treat cancers ...
Please provide your email address to receive an email when new articles are posted on . A Swiss biopharmaceutical company announced its launch with $63 million in Series A financing for research and ...
CARMEL, Ind.--(BUSINESS WIRE)--Sudo Biosciences (“Sudo”), a biopharmaceutical company committed to designing and developing best-in-class precision TYK2 (tyrosine kinase 2) inhibitors, announced today ...
Recent clinical studies have suggested that phenylacetylglutamine (PAGln), a novel gut microbial metabolite, can mechanistically modulate patients' risk of developing cardiovascular disease (CVD) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback